CBST Share Price

Open 101.98 Change Price %
High 101.99 1 Day 0.14 0.14
Low 101.94 1 Week 0.00 0.00
Close 101.94 1 Month 0.00 0.00
Volume 7884444 1 Year 0.00 0.00
52 Week High 58.89
52 Week Low 0.00
CBST Important Levels
Resistance 2 101.99
Resistance 1 101.97
Pivot 101.96
Support 1 101.91
Support 2 101.89
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
ETRM 0.07 40.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.66 1.08%
MU 20.66 1.08%
More..
NASDAQ USA Top Gainers Stocks
SSH 0.58 176.19%
SSH 0.58 176.19%
SSH 0.58 176.19%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
IRG 0.43 72.00%
MBLX 0.51 64.52%
COOL 5.17 63.61%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
SHIP 1.20 -45.45%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST)

CBST Technical Analysis 5
As on 21st Jan 2015 CBST Share Price closed @ 101.94 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 73.20 & Strong Buy for SHORT-TERM with Stoploss of 87.65 we also expect STOCK to react on Following IMPORTANT LEVELS.
CBST Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CBST Other Details
Segment EQ
Market Capital 2782392320.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cubist.com
CBST Address
CBST
65 Hayden Avenue
Lexington, MA 02421
United States
Phone: 781-860-8660
CBST Latest News
Interactive Technical Analysis Chart Cubist Pharmaceuticals, Inc. ( CBST NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cubist Pharmaceuticals, Inc.
CBST Business Profile
Cubist Pharmaceuticals, Inc. (Cubist), incorporated in 1992, is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc. CUBICIN is a once-daily, bactericidal, intravenous, antibiotic with activity against methicillin-resistant Staphylococcus aureus (S. aureus). CUBICIN is approved in the United States and European Union for the treatment of certain Gram-positive bacteria and for certain bloodstream infections. ENTEREG is approved in the United States to accelerate upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. As of December 31, 2011, ENTEREG was not approved for marketing outside of the United States. DIFICID is used for the treatment of Clostridium difficile-associated diarrhea (CDAD). As of December 31, 2011, CUBICIN has been used in the treatment of approximately 1.4 million patients in the United States. As of December 31, 2011, CUBICIN was available in approximately 52 countries. CXA-201 is an intravenous antibiotic combination of an anti-pseudomonal cephalosporin. CB-315 is an oral lipopeptide with in vitro bactericidal activity against Clostridium difficile (C. difficile). CB-5945, a clinical-stage product candidate, is an oral, peripherally restricted mu opioid receptor antagonist.